StemoniX Wins Life Science/Health IT Division in MN Cup Competition

MN Cup Finalist
– Minneapolis, MN

StemoniX Wins Life Science/Health IT Division in MN Cup Competition

Will Next Compete for Grand Prize on Sept. 22


StemoniX, a company setting a new economic paradigm around stem cell technologies, today announced it has won the Life Science/Health IT division of the MN Cup competition.


StemoniX was one of more than 600 companies participating in the competition. By winning one of the eight divisions, StemoniX has advanced to compete for the Grand Prize, which will be awarded at the MN Cup Final Awards Reception on Sept. 22. MN Cup is the largest statewide new-business competition in the country.


“We are honored to represent the Life Science/Health IT division of the MN Cup. This recognition is a testament to our unique product offering and the progress we have made as a company,” said Ping Yeh, CEO and cofounder of StemoniX. “We have developed a platform to scale stem cell technologies, generated a strong intellectual property portfolio and we are meeting the needs of pharma clients. We are excited about our potential to help accelerate the discovery of medicines for the spectrum of diseases and pandemics from Autism to Zika.”


About StemoniX

StemoniX is leading the development and manufacturing of human induced pluripotent stem cells for academic and industrial pharmaceutical research and discovery applications, such as biologically accurate, miniaturized organ-like microtissues. Its biotechnology provides scientists the ultimate “in vitro” testing environment with standardized, easy-to-use, cost-effective access to relevant human microtissue for toxicity and efficacy screening. Incorporated in Minnesota, the company is co-located in Minneapolis and San Diego, Calif. For more information visit


To read more on University of Minnesota Carlson School of Managment website click here:

Interested in getting in touch? Send us an email or fill out a contact form and we will be happy to get back to you.

Leave a Reply